Oncolytic Virus and Checkpoint Antibody Combination Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, such as immunotherapies targeting immune checkpoint molecules, have limitations in effectively reducing tumor burden and improving survival rates, particularly in melanoma and other cancers, as they often rely on monotherapies that may not induce robust anti-tumor responses.
Innovation Solution
The combination of oncolytic Coxsackievirus A21 (CVA21) with immunostimulatory agents like anti-PD-1 or anti-CTLA-4 antibodies is administered directly to tumors or systemically, enhancing anti-tumor immunity by inducing viral replication and immune response, thereby acting as a personalized in situ cancer vaccine.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monotherapy with immunostimulatory agents (e.g., anti-PD-1 or anti-CTLA-4 antibodies) is used, then treatment simplicity is maintained, but anti-tumor response efficacy is insufficient
Solution Approach 1:
The patent combines oncolytic CVA21 virus with immuno-stimulatory agents (anti-PD-1 or anti-CTLA-4 antibodies) into a single combination therapy regimen. The oncolytic virus selectively infects and lyses tumor cells while the immuno-stimulatory agent blocks immune checkpoint molecules, and their synergistic interaction enhances anti-tumor immunity beyond what either agent achieves alone, resolving the contradiction between treatment simplicity and efficacy.
2Reliability
If oncolytic virus alone is administered, then tumor cell lysis is achieved, but systemic immune response is insufficient
Solution Approach 1:
The patent merges oncolytic CVA21 virus administration with immuno-stimulatory antibody administration into a unified treatment protocol. The oncolytic virus provides localized tumor cell lysis and releases tumor antigens, while the combined immuno-stimulatory agent amplifies the systemic immune response to these antigens, achieving robust systemic immunity that neither agent can produce alone.
3Productivity
If combination therapy with oncolytic virus and immuno-stimulatory agent is used, then tumor burden reduction is enhanced, but treatment cost and complexity increase
Solution Approach 1:
The patent integrates oncolytic CVA21 and immuno-stimulatory agents into a coordinated combination therapy where the oncolytic virus preferentially replicates in tumor cells causing lysis, while the immuno-stimulatory agent blocks checkpoint inhibition. This merging of mechanisms produces a synergistic effect that accelerates tumor burden reduction beyond additive effects, justifying the increased treatment complexity through superior clinical outcomes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly reduces tumor burden, retards tumor growth, and prolongs survival by stimulating a systemic immune response, offering a synergistic effect that surpasses the efficacy of either treatment alone, as demonstrated in murine melanoma models.
Implementation Method 1
delivering an oncolytic virus or oncolytic viral RNA via direct injection or systemic administration to the tumour
Implementation Method 2
co-administration of an immuno-stimulatory agent which specifically binds to an immune checkpoint molecule selected from the group consisting of CTLA-4 and PD-1
Implementation Method 3
thereby acting as a personalised in situ cancer vaccine
Data Source
AI summary
The invention relates to methods of treating tumours comprising delivering an oncolytic virus or oncolytic viral RNA via direct injection or systemic administration or intravesicular administration to the tumour or cancer in combination with the co-administration of an immuno-stimulatory agent via the systemic route to a mammal.